Kura Oncology, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
KURA Nasdaq 2834 kuraoncology.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Kura Oncology, Inc.

Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones - Jan 11th, 2026 3:00 pm
How Komzifti Is Rewriting The Kura Oncology (KURA) Story For Analysts And Investors - Jan 9th, 2026 5:17 pm
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 5th, 2026 5:30 am
Jim Cramer Discusses Kura Oncology as a Speculative Bet - Dec 21st, 2025 8:26 am
How the Narrative Surrounding Kura Oncology Is Changing After Komzifti Approval - Dec 20th, 2025 1:10 am
Kura Oncology (KURA) Gains Momentum as Barclays Sees Significant Potential in Ziftomenib Approval - Dec 15th, 2025 9:10 pm
Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML - Dec 8th, 2025 8:30 am
Why The Narrative Around Kura Oncology Is Shifting After Komzifti’s FDA Breakthrough - Dec 5th, 2025 11:14 pm
Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia - Dec 3rd, 2025 6:32 am
First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin - Dec 2nd, 2025 6:02 am
KOMZIFTI™ (ziftomenib) Added to National Comprehensive Cancer Network® (NCCN) Guidelines for Acute Myeloid Leukemia (AML) - Nov 25th, 2025 3:16 pm
Kura Oncology (KURA) Is Up 8.1% After FDA Approval of KOMZIFTI for NPM1-Mutated AML – What's Changed - Nov 25th, 2025 3:08 am
Why The Narrative Around Kura Oncology Is Shifting After FDA Approval and Analyst Upgrades - Nov 21st, 2025 12:09 pm
Kura and Kyowa Kirin secure FDA go-ahead for targeted leukaemia therapy - Nov 14th, 2025 5:15 am
Lundbeck sparks bidding war with Alkermes; Pfizer closes Metsera deal - Nov 14th, 2025 4:06 am
Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI™ (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia - Nov 13th, 2025 8:51 am
Kura Oncology to Participate in Upcoming Investor Conference - Nov 12th, 2025 2:05 pm
How Recent Events Are Rewriting the Story for Kura Oncology - Nov 7th, 2025 11:11 am
Kura Oncology (KURA): Persistent Losses Undercut Rapid 42.7% Revenue Growth Narrative - Nov 4th, 2025 7:22 pm
Kura Oncology Inc (KURA) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Rising Expenses - Nov 4th, 2025 2:03 pm